Abstract
Introduction
An increase in public funding for research and a heightened interest among
drug developers suggest that a breakthrough in autism spectrum disorder (ASD)
treatment may be imminent. However, drug development has been slow, plagued by
a limited understanding of the disease and the diffi culties in developing
treatments for pediatric populations in general and in ASD in particular.
However, substantial opportunity exists for an agent that can safely improve
an autistic child' s ability to interact and adapt to his or her surroundings.
Questions Answered in This Report
- ASD includes three distinct diagnoses: Asperger' s disorder, classic aut
ism, and pervasive development disorder - not otherwise specifi ed. What are
the common symptoms in these disorders? How do they differ from one another?
What is known about the cause of the disease?
- Public awareness of ASD has increased substantially over the last ten
years, and Decision Resources has conducted a comprehensive review of the
epidemiology of this indication. How many children in the United States are
diagnosed with ASD? How will this population grow over the next ten years? How is ASD diagnosed?
- Janssen' s Risperdal is the only agent approved for the treatment of ASD.
What are the goals of drug treatment in ASD? How effective are current
therapies? What is the potential of emerging agents?
- One interviewed thought leader treating ASD characterizes current
treatments as "throwing a dart at the board." What do thought leaders say
about emerging approaches? Why does glutamate excitotoxicity particularly
intrigue them? What treatment challenges and needs do they identify?
Scope
- Overview of ASD: Disease description and symptoms, etiology, diagnosis.
- Epidemiology: Prevalent cases of ASD in the United States, forecasted
prevalence to 2018, evaluation of trends in ASD prevalence.
- Primary research: Interviews with thought-leading specialists treating ASD
as well as their opinions on current and emerging agents and treatment
dynamics.
- Current treatments: Atypical antipsychotics, antidepressants, stimulants,
antiepileptics, complementary and alternative medicine (CAM).
- Emerging treatments: Forest Laboratories/Merz' s Namenda (memantine),
BioMarin' s Kuvan, Seaside Therapeutics' STX-209, Curemark' s CM-AT. Outlook:
2008 major-market (United States, France, Germany, Italy, Spain, United
Kingdom, and Japan) sales, potential of emerging agents.
Mentioned in This Report
Companies
- Abbott
- AstraZeneca
- BioMarin Pharmaceutical
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Curemark
- Eli Lilly
- Forest Laboratories
- GlaxoSmithKline
- Janssen
- Janssen-Cilag
- Lundbeck
- McNeil Pediatrics
- MDRNA
- Merz
- Neuropharm
- Novartis
- Ortho-McNeil
- Otsuka Pharmaceutical
- Pfi zer
- Seaside Therapeutics
- Shire
|
Related Report
|
View Cart
